Search Results for "Colchicine And Rivaroxaban"

13:49 EST 4th March 2015 | BioPortfolio

Matching Channels


Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...

Matching News

BRIEF-Hikma Pharma says preparing to distribute Colchicine

* Prepare to distribute its colchicine, which it will market under brand name mitigare

COPPS-2: Colchicine Stops Postop Pericarditis, Troubles Gut

In COPPS-2, patients taking colchicine had a high rate of adverse GI events, and this likely explains why there was no overall benefit in preventing AF after cardiac surgery; but it was effective ...

Takeda’s Take On Patent Certification Rules In Colchicine Dispute Rejected

A federal judge tosses Takeda’s suit against FDA, finding Hikma did not need to reference Takeda’s Colcrys or certify Colcrys patents to obtain approval of its colchicine product.

Rivaroxaban Viable as Alternative Anticoagulant for Cardioversion

The oral anticoagulant rivaroxaban appears to safely and effectively prevent the risk of stroke associated with cardioversion in patients with atrial fibrillation, according to a randomized trial of 1...

Colchicine 'Useless' for Postop Pericardial Effusion: POPE-2

In yet another trial, colchicine did not reduce complications after cardiac surgery; specifically, the drug failed to decrease postoperative pericardial effusion volume or prevent cardiac tamponad...

Hikma to launch colchicine in USA as Takeda’s injunction fails

Jordon-headquartered Hikma Pharmaceuticals saw its shares rise 4.2% to a record high of £23.80, after a USA appeals court rejected Japanese drug major Takeda Pharmaceutical’s bid to bock the firm...

Rivaroxaban vs Vitamin K Antagonists for Cardioversion in AF

Does oral rivaroxaban help to fast-track patients for cardioversion? European Heart Journal

Prasco to market authorized colchicine generic in the US

US generics maker, Prasco Laboratories (Prasco), announced on 12 January 2015 that it had entered into an alliance with the US subsidiary of Japanese pharmaceutical company, Takeda, to distribute an a...

Matching PubMed Articles

Colchicine: Old and New.

Although colchicine has been a focus of research, debate and controversy for thousands of years, it was only approved by the United States Food and Drug Administration in 2009. Over the past decade, a...

Colchicine for the prevention of pericarditis: what we know and what we do not know in 2014 - systematic review and meta-analysis.

The purpose of this study was to investigate and summarize available evidence on the efficacy and safety of colchicine for pericarditis prevention. Disease recurrence is the major and most common comp...

Rivaroxaban for Treatment of Venous Thromboembolism in Older Adults.

Rivaroxaban is a factor Xa inhibitor recently approved for use in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). Older adults are at an increased risk for venous thromboembol...

Effect of rivaroxaban on fibrinolytic therapy in massive pulmonary embolism: two cases.

The risk of dying from a pulmonary embolism (PE) is estimated to be about 30% if inotropic support is required and no cardiopulmonary arrest occurs. Fibrinolysis in massive PE is regarded as a life-sa...

Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism.

Rivaroxaban is non-inferior to warfarin for the treatment of venous thromboembolism, with regard to clinical efficacy and safety. The ex-vivo effects of warfarin versus therapeutic dose rivaroxaban on...

Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement